Cargando…

Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry

Mucopolysaccharidosis type II (MPS II; Hunter syndrome; OMIM 309900) is a rare lysosomal storage disease with progressive multisystem manifestations caused by deficient activity of the enzyme iduronate-2-sulfatase. Disease-specific treatment is available in the form of enzyme replacement therapy wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muenzer, Joseph, Jones, Simon A., Tylki-Szymańska, Anna, Harmatz, Paul, Mendelsohn, Nancy J., Guffon, Nathalie, Giugliani, Roberto, Burton, Barbara K., Scarpa, Maurizio, Beck, Michael, Jangelind, Yvonne, Hernberg-Stahl, Elizabeth, Larsen, Maria Paabøl, Pulles, Tom, Whiteman, David A. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414331/ https://www.ncbi.nlm.nih.gov/pubmed/28464912 http://dx.doi.org/10.1186/s13023-017-0635-z

Ejemplares similares

Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2017)

Birth weight in patients with mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS)
por: Bodamer, Olaf, et al.
Publicado: (2017)

Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2021)

Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS)
por: Ficicioglu, Can, et al.
Publicado: (2017)

The role of enzyme replacement therapy in severe Hunter syndrome—an expert panel consensus
por: Muenzer, Joseph, et al.
Publicado: (2011)

A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4–7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy
por: Giugliani, Roberto, et al.
Publicado: (2014)

Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey
por: Link, Bianca, et al.
Publicado: (2010)

Diagnosis and Management of Mucopolysaccharidosis Type II (Hunter Syndrome) in Poland
por: Żuber, Zbigniew, et al.
Publicado: (2023)

The Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) Questionnaire: item reduction and further validation
por: Wiklund, Ingela, et al.
Publicado: (2014)

Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls
por: Burton, Barbara K., et al.
Publicado: (2012)

Clinical characteristics and surgical history of Taiwanese patients with mucopolysaccharidosis type II: data from the hunter outcome survey (HOS)
por: Lin, Hsiang-Yu, et al.
Publicado: (2018)

Satellitstation hos CERN
Publicado: (1977)

Impact of the COVID-19 pandemic on the standard of care for patients with lysosomal storage diseases: A survey of healthcare professionals in the Fabry, Gaucher, and Hunter Outcome Survey registries
por: Elstein, Deborah, et al.
Publicado: (2021)

Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment
por: Hendriksz, Christian J., et al.
Publicado: (2015)

Use of HOS Data in Florida
por: McDonald, Kathie, et al.
Publicado: (2004)

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
por: Wraith, J. Edmond, et al.
Publicado: (2007)

Response to: Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome
por: Eisengart, J.B., et al.
Publicado: (2020)

The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome
por: Eisengart, J.B., et al.
Publicado: (2019)

Assessing the impact of the five senses on quality of life in mucopolysaccharidoses
por: Giugliani, Roberto, et al.
Publicado: (2020)

Timing is everything: Clinical courses of Hunter syndrome associated with age at initiation of therapy in a sibling pair
por: Grant, Nathan, et al.
Publicado: (2022)

Airway Findings in Patients with Hunter Syndrome Treated with Intravenous Idursulfase
por: De Vuyst, Richard, et al.
Publicado: (2023)

Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients
por: Giugliani, R., et al.
Publicado: (2017)

Diverse clinical outcome of Hunter syndrome in patients with chromosomal aberration encompassing entire and partial IDS deletions: what is important for early diagnosis and counseling?
por: Jezela-Stanek, Aleksandra, et al.
Publicado: (2020)

Return of the Repressed: Bong Joon-Ho’s Parasite
por: Ridgeway-Diaz, Julia, et al.
Publicado: (2020)

Underwater Target Perception in Local HOS Space
por: Gao, Jue, et al.
Publicado: (2021)

Estimation of Non-Response Bias in the Medicare FFS HOS
por: McCall, Nancy, et al.
Publicado: (2004)

HOS Highlights: Functional Impairment Levels in PACE Enrollees
por: Walsh, Edith G., et al.
Publicado: (2008)

Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry
por: Beck, Michael, et al.
Publicado: (2022)

Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future
por: Whiteman, David AH, et al.
Publicado: (2017)

Development of a mnemonic screening tool for identifying subjects with Hunter syndrome
por: Cohn, Gabriel M., et al.
Publicado: (2013)

Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study
por: Guffon, Nathalie, et al.
Publicado: (2015)

Easy‐to‐use algorithm would provide faster diagnoses for mucopolysaccharidosis type I and enable patients to receive earlier treatment
por: Tylki‐Szymańska, Anna, et al.
Publicado: (2018)

Functional characterization of Candida albicans Hos2 histone deacetylase
por: Karthikeyan, G, et al.
Publicado: (2014)

Measuring and Improving Health Outcomes in Medicare: The Medicare HOS Program
por: Haffer, Samuel C. (Chris), et al.
Publicado: (2004)

The psychometric properties of the Italian adaptation of the Health Orientation Scale (HOS)
por: Masiero, M., et al.
Publicado: (2020)

The role of corepressor HOS15-mediated epigenetic regulation of flowering
por: Huang, Li-Jun, et al.
Publicado: (2023)

Clinical characteristics and somatic burden of patients with mucopolysaccharidosis II with or without neurological involvement: An analysis from the Hunter Outcome Survey
por: Lau, Heather, et al.
Publicado: (2023)

International working group identifies need for newborn screening for mucopolysaccharidosis type I but states that existing hurdles must be overcome
por: Parini, Rossella, et al.
Publicado: (2018)

The natural history of MPS I: global perspectives from the MPS I Registry
por: Beck, Michael, et al.
Publicado: (2014)

The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life
por: Raluy-Callado, Mireia, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_v6n9dal62ohp4ckb7sg40ei5go